New metal complexes as potential therapeutics

被引：896

作者：

Zhang, CX ^{[1
]}

Lippard, SJ ^{[1
]}

机构：

[1] MIT, Dept Chem, Cambridge, MA 01239 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2003年 / 7卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(03)00081-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The many activities of metal ions in biology have stimulated the development of metal-based therapeutics. Cisplatin, as one of the leading metal-based drugs, is widely used in treatment of cancer, being especially effective against genitourinary tumors such as testicular. Significant side effects and drug resistance, however, have limited its clinical applications. Biological carriers conjugated to cisplatin analogs have improved specificity for tumor tissue, thereby reducing side effects and drug resistance. Platinum complexes with distinctively different DNA binding modes from that of cisplatin also exhibit promising pharmacological properties. Ruthenium and gold complexes with antitumor activity have also evolved. Other metal-based chemotherapeutic compounds have been investigated for potential medicinal applications, including superoxide dismutase mimics and metal-based NO donors/scavengers. These compounds have the potential to modulate the biological properties of superoxide anion and nitric oxide.

引用

收藏

页码：481 / 489

页数：9

相关论文

共 70 条

[1] In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].

Aird, RE ;

Cummings, J ;

Ritchie, AA ;

Muir, M ;

Morris, RE ;

Chen, H ;

Sadler, PJ ;

Jodrell, DI .

BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657

[2] Metal complexes as photo- and radiosensitizers [J].

Ali, H ;

van Lier, JE .

CHEMICAL REVIEWS, 1999, 99 (09) :2379-2450

[3] Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease [J].

Aslan, M ;

Ryan, TM ;

Adler, B ;

Townes, TM ;

Parks, DA ;

Thompson, JA ;

Tousson, A ;

Gladwin, MT ;

Patel, RP ;

Tarpey, MM ;

Batinic-Haberle, I ;

White, CR ;

Freeman, BA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15215-15220

[4] SYNTHESIS, CHARACTERIZATION, AND DNA-BINDING PROPERTIES OF (1,2-DIAMINOETHANE)PLATINUM(II) COMPLEXES LINKED TO THE DNA INTERCALATOR ACRIDINE-ORANGE BY TRIMETHYLENE AND HEXAMETHYLENE CHAINS [J].

BOWLER, BE ;

AHMED, KJ ;

SUNDQUIST, WI ;

HOLLIS, LS ;

WHANG, EE ;

LIPPARD, SJ .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (04) :1299-1306

[5] Molecular aspects of resistance to antitumor platinum drugs [J].

Brabec, V ;

Kasparkova, J .

DRUG RESISTANCE UPDATES, 2002, 5 (3-4) :147-161

[6] Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells [J].

Briz, O ;

Serrano, MA ;

Rebollo, N ;

Hagenbuch, B ;

Meier, PJ ;

Koepsell, H ;

Marin, JJG .

MOLECULAR PHARMACOLOGY, 2002, 61 (04) :853-860

[7] Cytotoxic acridinylthiourea and its platinum conjugate produce enzyme-mediated DNA strand breaks [J].

Brow, JM ;

Pleatman, CR ;

Bierbach, U .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (20) :2953-2955

[8] Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes [J].

Buckley, RG ;

Elsome, AM ;

Fricker, SP ;

Henderson, GR ;

Theobald, BRC ;

Parish, RV ;

Howe, BP ;

Kelland, LR .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (26) :5208-5214

[9] Metal complexing agents as therapies for Alzheimer's disease [J].

Bush, AI .

NEUROBIOLOGY OF AGING, 2002, 23 (06) :1031-1038

[10] Ruthenium(III) polyaminocarboxylate complexes: Efficient and effective nitric oxide scavengers [J].

Cameron, BR ;

Darkes, MC ;

Yee, H ;

Olsen, M ;

Fricker, SP ;

Skerlj, RT ;

Bridger, GJ ;

Davies, NA ;

Wilson, MT ;

Rose, DJ ;

Zubieta, J .

INORGANIC CHEMISTRY, 2003, 42 (06) :1868-1876

← 1 2 3 4 5 6 7 →